Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.78 |
| ▸ | ADRB1 | P08588 | 19/20 | 0.78 |
| ▸ | DRD2 | P14416 | 9/20 | 0.78 |
| ▸ | DRD3 | P35462 | 3/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4532726 | 1.00 | ADRB2 (0.78) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL4521511 | 0.94 | ADRB2 (0.77) | ADRB2ADRB1DRD2ADRA1D | |
| SCHEMBL4521505 | 0.94 | ADRB2 (0.77) | ADRB2ADRB1DRD2ADRA1D | |
| SCHEMBL4521154 | 0.93 | ADRB2 (0.78) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL4521160 | 0.93 | ADRB2 (0.78) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL13711701 | 0.91 | ADRB2 (0.70) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL4513332 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL4519478 | 0.87 | ADRB2 (0.78) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL4519481 | 0.87 | ADRB2 (0.78) | ADRB2ADRB1DRD2DRD3ADRA1D | |
| SCHEMBL4531493 | 0.86 | ADRB2 (0.79) | ADRB2ADRB1DRD2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | claimed |
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-1937656-A1 | 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS BETA 2 ADRENOCEPTOR AGONISTS | AstraZeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007027134-A1 | 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS β2 ADRENOCEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885DRD2 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.